Latest Leadership Change News

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

Neurizon Therapeutics has secured an additional A$2.7 million through a placement addressing the shortfall from its entitlement offer, lifting total proceeds to approximately A$8.5 million. This fresh capital strengthens the biotech’s balance sheet and provides financial flexibility as it advances its lead ALS drug NUZ-001 through pivotal clinical stages.

Nutritional Growth Solutions has appointed director Manik Pujara as interim CEO and CFO, replacing Andrew Grover who remains as nonexecutive chair. This leadership shuffle coincides with ongoing exploration of corporate opportunities.

Lightning Minerals pivots to a gold-led Australian strategy, elevating its Mt Turner Project as the core value driver while shedding non-core lithium assets. The company aims to capitalise on strong initial drilling success and disciplined capital allocation amid evolving commodity cycles.

Castle Minerals has consolidated a dominant 184 km² landholding in Western Australia’s Murchison Gold District and advanced Côte d’Ivoire exploration toward drill-ready targets, supported by strategic leadership appointments.

Noronex completed maiden drilling programs at key uranium and copper projects while bolstering its cash position through strategic asset sales. The company also formalised a 51% stake in its Etango North uranium project and navigates a CEO transition.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Magnum Mining names Antonio Vitor Junior as Managing Director to spearhead major drilling campaigns at its Azimuth and Parker projects, aiming to convert promising early rare earth results into a formal resource.

Shine Justice reshuffles its top management as Simon Morrison steps down from Managing Director to Executive Director to spearhead international growth, particularly in its burgeoning mass torts program, while Carolyn Barker AM maintains overall CEO leadership.

Nufarm reports a robust first half of FY26 with underlying EBITDA rising 17% and net debt falling by $130 million, while new CEO Rico Christensen initiates a $50 million cost savings program as part of a strategic refresh.

Genetic Signatures has locked in a 10-year supply deal with Denmark’s Hvidovre Hospital for its EasyScreen™ Pan-Enteric assay, marking a significant step in its European expansion. The agreement covers 28,000 tests in the first year with growth expected, leveraging the company’s proprietary 3base® technology to streamline complex gastrointestinal pathogen detection.

Noxopharm Limited's CEO and Managing Director Dr Gisela Mautner has resigned after four years with the company, including leading a key strategic pivot. The biotech firm plans to announce her successor shortly.